Analysis of Long-term (Investment) Activity Ratios
Beginner level
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Eli Lilly & Co., long-term (investment) activity ratios
Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Eli Lilly & Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Eli Lilly & Co.’s total asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Eli Lilly & Co.’s equity turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |
Net Fixed Asset Turnover
Eli Lilly & Co., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenue | 22,319,500 | 24,555,700 | 22,871,300 | 21,222,100 | 19,958,700 | |
| Property and equipment, net | 7,872,900 | 8,919,500 | 8,826,500 | 8,252,600 | 8,053,500 | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 2.83 | 2.75 | 2.59 | 2.57 | 2.48 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | 3.97 | 4.04 | 3.60 | 3.66 | 3.56 | |
| AbbVie Inc. | 11.23 | 11.36 | 10.07 | 9.85 | 8.91 | |
| Allergan PLC | 8.35 | 8.83 | 8.93 | 9.04 | 9.58 | |
| Amgen Inc. | 4.51 | 4.54 | 4.37 | 4.41 | 4.27 | |
| Biogen Inc. | 4.43 | 3.74 | 3.86 | 4.58 | 4.92 | |
| Bristol-Myers Squibb Co. | 4.18 | 4.49 | 4.15 | 3.90 | 3.75 | |
| Gilead Sciences Inc. | 4.91 | 5.41 | 7.79 | 10.45 | 14.13 | |
| Illumina Inc. | 3.99 | 3.10 | 2.96 | 3.36 | 6.48 | |
| Johnson & Johnson | 4.65 | 4.79 | 4.50 | 4.52 | 4.41 | |
| Merck & Co. Inc. | 3.11 | 3.18 | 3.23 | 3.31 | 3.16 | |
| Pfizer Inc. | 3.71 | 4.01 | 3.79 | 3.97 | 3.55 | |
| Regeneron Pharmaceuticals Inc. | 2.72 | 2.61 | 2.49 | 2.33 | 2.57 | |
| Vertex Pharmaceuticals Inc. | 5.59 | 3.75 | 3.15 | 2.44 | 1.48 | |
| Zoetis Inc. | 3.23 | 3.51 | 3.70 | 3.54 | 3.65 | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | 4.21 | 4.29 | 4.18 | 4.31 | 4.23 | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 6.03 | 6.09 | 5.89 | 6.09 | 5.74 | |
Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).
1 2019 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 22,319,500 ÷ 7,872,900 = 2.83
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Eli Lilly & Co.’s net fixed asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Eli Lilly & Co., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenue | 22,319,500 | 24,555,700 | 22,871,300 | 21,222,100 | 19,958,700 | |
| Property and equipment, net | 7,872,900 | 8,919,500 | 8,826,500 | 8,252,600 | 8,053,500 | |
| Operating lease assets | 532,100 | — | — | — | — | |
| Property and equipment, net (including operating lease, right-of-use asset) | 8,405,000 | 8,919,500 | 8,826,500 | 8,252,600 | 8,053,500 | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.66 | 2.75 | 2.59 | 2.57 | 2.48 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| Abbott Laboratories | 3.56 | 4.04 | 3.60 | 3.66 | 3.56 | |
| AbbVie Inc. | 10.06 | 11.36 | 10.07 | 9.85 | 8.91 | |
| Allergan PLC | 6.66 | 8.83 | 8.93 | 9.04 | 9.58 | |
| Amgen Inc. | 4.11 | 4.54 | 4.37 | 4.41 | 4.27 | |
| Biogen Inc. | 3.91 | 3.74 | 3.86 | 4.58 | 4.92 | |
| Bristol-Myers Squibb Co. | 3.76 | 4.49 | 4.15 | 3.90 | 3.75 | |
| Gilead Sciences Inc. | 4.28 | 5.41 | 7.79 | 10.45 | 14.13 | |
| Illumina Inc. | 2.45 | 3.10 | 2.96 | 3.36 | 6.48 | |
| Johnson & Johnson | 4.41 | 4.79 | 4.50 | 4.52 | 4.41 | |
| Merck & Co. Inc. | 2.90 | 3.18 | 3.23 | 3.31 | 3.16 | |
| Pfizer Inc. | 3.39 | 4.01 | 3.79 | 3.97 | 3.55 | |
| Regeneron Pharmaceuticals Inc. | 2.70 | 2.61 | 2.49 | 2.33 | 2.57 | |
| Vertex Pharmaceuticals Inc. | 5.00 | 3.75 | 3.15 | 2.44 | 1.48 | |
| Zoetis Inc. | 2.94 | 3.51 | 3.70 | 3.54 | 3.65 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals & Biotechnology | 3.85 | 4.29 | 4.18 | 4.31 | 4.23 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 5.38 | 6.09 | 5.89 | 6.09 | 5.74 | |
Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).
1 2019 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 22,319,500 ÷ 8,405,000 = 2.66
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Eli Lilly & Co.’s net fixed asset turnover ratio (with operating lease, right-of-use asset) improved from 2017 to 2018 but then slightly deteriorated from 2018 to 2019 not reaching 2017 level. |
Total Asset Turnover
Eli Lilly & Co., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenue | 22,319,500 | 24,555,700 | 22,871,300 | 21,222,100 | 19,958,700 | |
| Total assets | 39,286,100 | 43,908,400 | 44,981,000 | 38,805,900 | 35,568,900 | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.57 | 0.56 | 0.51 | 0.55 | 0.56 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| Abbott Laboratories | 0.47 | 0.46 | 0.36 | 0.40 | 0.49 | |
| AbbVie Inc. | 0.37 | 0.55 | 0.40 | 0.39 | 0.43 | |
| Allergan PLC | 0.17 | 0.16 | 0.13 | 0.11 | 0.11 | |
| Amgen Inc. | 0.37 | 0.34 | 0.27 | 0.28 | 0.29 | |
| Biogen Inc. | 0.53 | 0.53 | 0.52 | 0.50 | 0.55 | |
| Bristol-Myers Squibb Co. | 0.20 | 0.64 | 0.62 | 0.58 | 0.52 | |
| Gilead Sciences Inc. | 0.36 | 0.34 | 0.37 | 0.53 | 0.62 | |
| Illumina Inc. | 0.48 | 0.48 | 0.52 | 0.56 | 0.60 | |
| Johnson & Johnson | 0.52 | 0.53 | 0.49 | 0.51 | 0.53 | |
| Merck & Co. Inc. | 0.55 | 0.51 | 0.46 | 0.42 | 0.39 | |
| Pfizer Inc. | 0.31 | 0.34 | 0.31 | 0.31 | 0.29 | |
| Regeneron Pharmaceuticals Inc. | 0.53 | 0.57 | 0.67 | 0.70 | 0.73 | |
| Vertex Pharmaceuticals Inc. | 0.50 | 0.49 | 0.70 | 0.59 | 0.41 | |
| Zoetis Inc. | 0.54 | 0.54 | 0.62 | 0.64 | 0.60 | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | 0.38 | 0.43 | 0.38 | 0.38 | 0.38 | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.49 | 0.53 | 0.48 | 0.48 | 0.46 | |
Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).
1 2019 Calculation
Total asset turnover = Revenue ÷ Total assets
= 22,319,500 ÷ 39,286,100 = 0.57
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Eli Lilly & Co.’s total asset turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |
Equity Turnover
Eli Lilly & Co., equity turnover calculation, comparison to benchmarks
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenue | 22,319,500 | 24,555,700 | 22,871,300 | 21,222,100 | 19,958,700 | |
| Total Eli Lilly and Company shareholders’ equity | 2,606,900 | 9,828,700 | 11,592,200 | 14,007,700 | 14,571,300 | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 8.56 | 2.50 | 1.97 | 1.52 | 1.37 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| Abbott Laboratories | 1.03 | 1.00 | 0.89 | 1.02 | 0.96 | |
| AbbVie Inc. | — | — | 5.54 | 5.53 | 5.79 | |
| Allergan PLC | 0.28 | 0.24 | 0.22 | 0.19 | 0.20 | |
| Amgen Inc. | 2.30 | 1.80 | 0.86 | 0.73 | 0.75 | |
| Biogen Inc. | 1.08 | 1.03 | 0.97 | 0.94 | 1.15 | |
| Bristol-Myers Squibb Co. | 0.51 | 1.61 | 1.77 | 1.20 | 1.16 | |
| Gilead Sciences Inc. | 0.98 | 1.01 | 1.26 | 1.59 | 1.73 | |
| Illumina Inc. | 0.77 | 0.89 | 1.00 | 1.09 | 1.20 | |
| Johnson & Johnson | 1.38 | 1.37 | 1.27 | 1.02 | 0.98 | |
| Merck & Co. Inc. | 1.81 | 1.58 | 1.17 | 0.99 | 0.88 | |
| Pfizer Inc. | 0.82 | 0.85 | 0.74 | 0.89 | 0.75 | |
| Regeneron Pharmaceuticals Inc. | 0.71 | 0.77 | 0.96 | 1.09 | 1.12 | |
| Vertex Pharmaceuticals Inc. | 0.68 | 0.69 | 1.23 | 1.47 | 1.10 | |
| Zoetis Inc. | 2.31 | 2.67 | 3.00 | 3.29 | 4.46 | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals & Biotechnology | 1.10 | 1.16 | 0.97 | 0.92 | 0.88 | |
| Equity Turnover, Industry | ||||||
| Health Care | 1.30 | 1.35 | 1.20 | 1.17 | 1.08 | |
Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).
1 2019 Calculation
Equity turnover = Revenue ÷ Total Eli Lilly and Company shareholders’ equity
= 22,319,500 ÷ 2,606,900 = 8.56
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Eli Lilly & Co.’s equity turnover ratio improved from 2017 to 2018 and from 2018 to 2019. |